## Naoki Okada

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1635775/publications.pdf

Version: 2024-02-01

		81900	98798
143	5,434	39	67
papers	citations	h-index	g-index
155	155	155	5453
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials, 2015, 57, 50-58.	11.4	439
2	Development and Clinical Study of a Self-Dissolving Microneedle Patch for Transcutaneous Immunization Device. Pharmaceutical Research, 2013, 30, 2664-2674.	3.5	343
3	Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. Journal of Controlled Release, 2002, 82, 51-61.	9.9	177
4	Modulation of Intestinal P-Glycoprotein Function by Cremophor EL and Other Surfactants by an In Vitro Diffusion Chamber Method Using the Isolated Rat Intestinal Membranes. Journal of Pharmaceutical Sciences, 2004, 93, 877-885.	3.3	144
5	The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL- $1\hat{l}^2$ production, ROS production and endosomal rupture. Biomaterials, 2010, 31, 6833-6842.	11.4	136
6	Enhanced Permeability of Insulin across the Rat Intestinal Membrane by Various Absorption Enhancers: Their Intestinal Mucosal Toxicity and Absorption-enhancing Mechanism of n-Lauryl-Î <sup>2</sup> -D-maltopyranoside. Journal of Pharmacy and Pharmacology, 2010, 51, 1241-1250.	2.4	134
7	Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. Journal of Controlled Release, 2012, 160, 495-501.	9.9	124
8	Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. International Journal of Pharmaceutics, 2006, 313, 49-56.	5.2	114
9	A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. Journal of Controlled Release, 2012, 161, 10-17.	9.9	108
10	Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. Journal of Controlled Release, 2007, 122, 102-110.	9.9	98
11	Effects of Labrasol and Other Pharmaceutical Excipients on the Intestinal Transport and Absorption of Rhodamine 123, a P-Glycoprotein Substrate, in Rats. Biological and Pharmaceutical Bulletin, 2007, 30, 1301-1307.	1.4	95
12	A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. Journal of Controlled Release, 2009, 133, 198-205.	9.9	85
13	Efficient Gene Delivery into Dendritic Cells by Fiber-Mutant Adenovirus Vectors. Biochemical and Biophysical Research Communications, 2001, 282, 173-179.	2.1	83
14	Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors. Human Gene Therapy, 2007, 18, 753-762.	2.7	83
15	Titanium dioxide induces different levels of IL- $\hat{\Pi}^2$ production dependent on its particle characteristics through caspase-1 activation mediated by reactive oxygen species and cathepsin B. Biochemical and Biophysical Research Communications, 2010, 392, 160-165.	2.1	83
16	Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system. International Journal of Pharmaceutics, 2013, 441, 570-579.	5.2	81
17	Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells, 2020, 9, 1182.	4.1	81
18	Development of amphiphilic $\hat{l}^3$ -PGA-nanoparticle based tumor vaccine: Potential of the nanoparticulate cytosolic protein delivery carrier. Biochemical and Biophysical Research Communications, 2008, 366, 408-413.	2.1	80

#	Article	IF	CITATIONS
19	Nanoparticles built by self-assembly of amphiphilic $\hat{l}^3$ -PGA can deliver antigens to antigen-presenting cells with high efficiency: A new tumor-vaccine carrier for eliciting effector T cells. Vaccine, 2008, 26, 1303-1313.	3.8	79
20	Development of PEGylated adenovirus vector with targeting ligand. International Journal of Pharmaceutics, 2008, 354, 3-8.	5.2	78
21	A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. Journal of Controlled Release, 2008, 131, 113-120.	9.9	78
22	Functional and molecular identification of sodiumâ€coupled dicarboxylate transporters in rat primary cultured cerebrocortical astrocytes and neurons. Journal of Neurochemistry, 2006, 97, 162-173.	3.9	72
23	Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites. Journal of Controlled Release, 2001, 76, 363-374.	9.9	64
24	Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery. Biomaterials, 2009, 30, 1809-1814.	11.4	62
25	Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu1,7]-eel calcitonin in rats. Journal of Controlled Release, 2005, 106, 287-297.	9.9	60
26	Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. Journal of Controlled Release, 2011, 149, 15-20.	9.9	54
27	Intranasal immunization with poly( $\hat{l}^3$ -glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. Journal of Controlled Release, 2011, 152, 310-316.	9.9	53
28	Enhanced Absorption of Insulin and (Asu1,7)Eelâ€Calcitonin using Novel Azopolymerâ€Coated Pellets for Colonâ€Specific Drug Delivery. Journal of Pharmaceutical Sciences, 2001, 90, 89-97.	3.3	52
29	Ï, Receptor Ligand-Induced Up-Regulation of the H+/Peptide Transporter PEPT1 in the Human Intestinal Cell Line Caco-2. Biochemical and Biophysical Research Communications, 1999, 261, 242-246.	2.1	50
30	Suppression of nanosilica particle-induced inflammation by surface modification of the particles. Archives of Toxicology, 2012, 86, 1297-1307.	4.2	49
31	Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Therapy, 2005, 12, 72-83.	4.6	47
32	Chitosan Oligomers as Potential and Safe Absorption Enhancers for Improving the Pulmonary Absorption of Interferon-α in Rats. Journal of Pharmaceutical Sciences, 2005, 94, 2432-2440.	3.3	47
33	Vaccine efficacy of transcutaneous immunization with amyloid $\hat{l}^2$ using a dissolving microneedle array in a mouse model of Alzheimer's disease. Journal of Neuroimmunology, 2014, 266, 1-11.	2.3	47
34	CCâ€chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumorâ€infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. International Journal of Cancer, 2007, 121, 2013-2022.	5.1	46
35	Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery. Vaccine, 2013, 31, 2403-2415.	3.8	46
36	Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. Biochemical and Biophysical Research Communications, 2004, 317, 68-76.	2.1	45

#	Article	IF	Citations
37	Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. Biochemical and Biophysical Research Communications, 2020, 527, 350-357.	2.1	45
38	Functional characterization of brain peptide transporter in rat cerebral cortex: identification of the high-affinity type H+/peptide transporter PEPT2. Brain Research, 2004, 997, 52-61.	2.2	42
39	Transport characteristics of N â€acetyl―l â€aspartate in rat astrocytes: involvement of sodiumâ€coupled highâ€affinity carboxylate transporter NaC3/NaDC3â€mediated transport system. Journal of Neurochemistry, 2005, 93, 706-714.	3.9	40
40	Dendritic Cells That Endocytosed Antigen-Containing IgG-Liposomes Elicit Effective Antitumor Immunity. Journal of Immunotherapy, 2006, 29, 165-174.	2.4	40
41	Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats. Pharmaceutical Research, 2000, 17, 1461-1467.	<b>3.</b> 5	39
42	Development of a novel therapeutic approach using a retinoic acid-loaded microneedle patch for seborrheic keratosis treatment and safety study in humans. Journal of Controlled Release, 2013, 171, 93-103.	9.9	39
43	Improvement of absorption enhancing effects of n-dodecyl-β-d-maltopyranoside by its colon-specific delivery using chitosan capsules. International Journal of Pharmaceutics, 2005, 293, 127-135.	<b>5.</b> 2	38
44	Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Therapy, 2003, 10, 421-431.	4.6	37
45	Induction of Endoplasmic Reticulum–Endosome Fusion for Antigen Cross-Presentation Induced by Poly (γ-Glutamic Acid) Nanoparticles. Journal of Immunology, 2011, 187, 6249-6255.	0.8	36
46	Immunological Studies of SK2 Hybridoma Cells Microencapsulated with Alginate-Poly(L)lysine-Alginate (APA) Membrane Following Allogeneic Transplantation. Biochemical and Biophysical Research Communications, 1997, 230, 524-527.	2.1	35
47	Immune Cell Recruitment and Cell-Based System for Cancer Therapy. Pharmaceutical Research, 2008, 25, 752-768.	3 <b>.</b> 5	35
48	Development of novel double-decker microneedle patches for transcutaneous vaccine delivery. International Journal of Pharmaceutics, 2017, 532, 374-383.	5 <b>.</b> 2	35
49	Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma. Biological and Pharmaceutical Bulletin, 2006, 29, 100-104.	1.4	34
50	Optimized PEGylated Adenovirus Vector Reduces the Anti-vector Humoral Immune Response against Adenovirus and Induces a Therapeutic Effect against Metastatic Lung Cancer. Biological and Pharmaceutical Bulletin, 2010, 33, 1540-1544.	1.4	34
51	Efficient generation of antigen-specific cellular immunity by vaccination with poly( $\hat{I}^3$ -glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Biochemical and Biophysical Research Communications, 2007, 362, 1069-1072.	2.1	32
52	Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine, 2012, 30, 1847-1854.	3.8	32
53	Functional linkage of H+/peptide transporter PEPT2 and Na+/H+ exchanger in primary cultures of astrocytes from mouse cerebral cortex. Brain Research, 2005, 1044, 33-41.	2.2	31
54	Tumor Vascular Targeted Delivery of Polymer-conjugated Adenovirus Vector for Cancer Gene Therapy. Molecular Therapy, 2011, 19, 1619-1625.	8.2	31

#	Article	IF	CITATIONS
55	Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells. Journal of Pharmacological Sciences, 2018, 137, 359-365.	2.5	31
56	Interaction of kyotorphin and brain peptide transporter in synaptosomes prepared from rat cerebellum: implication of high affinity type H+/peptide transporter PEPT2 mediated transport system. Neuroscience Letters, 1999, 271, 117-120.	2.1	30
57	Functional characterization of Na+-independent choline transport in primary cultures of neurons from mouse cerebral cortex. Neuroscience Letters, 2006, 393, 216-221.	2.1	30
58	Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood, 2013, 121, 2804-2813.	1.4	30
59	Clinical study of a retinoic acid-loaded microneedle patch for seborrheic keratosis or senile lentigo. Life Sciences, 2017, 168, 24-27.	4.3	29
60	Colon-specific delivery and enhanced colonic absorption of [Asu1,7]-eel calcitonin using chitosan capsules containing various additives in rats. Journal of Drug Targeting, 2006, 14, 165-172.	4.4	28
61	Simple PEG Conjugation of SPIO via an Auâ^'S Bond Improves Its Tumor Targeting Potency as a Novel MR Tumor Imaging Agent. Bioconjugate Chemistry, 2010, 21, 1026-1031.	3.6	28
62	Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(l) lysine-alginate membrane. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1360, 53-63.	3.8	27
63	Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9, 27.	4.5	27
64	Control of pulmonary absorption of water-soluble compounds by various viscous vehicles. International Journal of Pharmaceutics, 2004, 282, 141-149.	5.2	26
65	Anti-tumor Responses Induced by Chemokine CCL19 Transfected into an Ovarian Carcinoma Model via Fiber-Mutant Adenovirus Vector. Biological and Pharmaceutical Bulletin, 2005, 28, 1066-1070.	1.4	26
66	Optimization and Internalization Mechanisms of PEGylated Adenovirus Vector with Targeting Peptide for Cancer Gene Therapy. Biomacromolecules, 2012, 13, 2402-2409.	5.4	26
67	Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. Journal of Pharmacy and Pharmacology, 2010, 60, 1633-1641.	2.4	24
68	Transcutaneous vaccines – current and emerging strategies. Expert Opinion on Drug Delivery, 2013, 10, 485-498.	5.0	24
69	Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. Oncolmmunology, 2020, 9, 1734268.	4.6	24
70	Effects of lipofectin–antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. Biochimica Et Biophysica Acta - General Subjects, 2001, 1527, 97-101.	2.4	23
71	Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Therapy, 2005, 12, 608-616.	4.6	22
72	The short consensus repeats 1 and 2, not the cytoplasmic domain, of human CD46 are crucial for infection of subgroup B adenovirus serotype 35. Journal of Controlled Release, 2006, 113, 271-278.	9.9	22

#	Article	IF	CITATIONS
73	A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity. Journal of Controlled Release, 2007, 117, 11-19.	9.9	22
74	Transduction of adenovirus vectors modified with cell-penetrating peptides. Peptides, 2009, 30, 1548-1552.	2.4	22
75	Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Letters, 2002, 177, 57-63.	7.2	21
76	Tumor Necrosis Factor α-Gene Therapy for an Established Murine Melanoma Using RGB (Arg-Gly-Asp) Fiber-mutant Adenovirus Vectors. Japanese Journal of Cancer Research, 2002, 93, 436-444.	1.7	21
77	Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochimica Et Biophysica Acta - General Subjects, 2004, 1670, 172-180.	2.4	21
78	Synthesis of 15,20-triamide analogue with polar substituent on the phenyl ring of arenastatin A, an extremely potent cytotoxic spongean depsipeptide. Bioorganic and Medicinal Chemistry, 2006, 14, 7446-7457.	3.0	21
79	Enhanced transdermal delivery of phenylalanyl-glycine by chemical modification with various fatty acids. International Journal of Pharmaceutics, 2003, 250, 119-128.	<b>5.</b> 2	20
80	Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity. Journal of Controlled Release, 1995, 33, 447-451.	9.9	19
81	Evaluation of Insulin Permeability and Effects of Absorption Enhancers on Its Permeability by an in Vitro Pulmonary Epithelial System Using Xenopus Pulmonary Membrane Biological and Pharmaceutical Bulletin, 2001, 24, 385-389.	1.4	19
82	Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage. International Journal of Pharmaceutics, 2005, 293, 63-72.	5.2	19
83	NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy. Cancer Immunology, Immunotherapy, 2009, 58, 291-299.	4.2	19
84	Cyotomedical therapy for insulinopenic diabetes using microencapsulated pancreatic $\hat{l}^2$ cell lines. Life Sciences, 2002, 71, 1717-1729.	4.3	18
85	Non-Methylated CpG Motif Packaged into Fusogenic Liposomes Enhance Antigen-Specific Immunity in Mice. Biological and Pharmaceutical Bulletin, 2006, 29, 105-109.	1.4	18
86	Characterization of Transcutaneous Protein Delivery by a Hydrogel Patch in Animal, Human, and Tissue-Engineered Skin Models. Biological and Pharmaceutical Bulletin, 2011, 34, 586-589.	1.4	18
87	Antimetastatic effect of synthetic Glu-lle-Leu-Asp- Val peptide derivatives containing D-amino acids. Anti-Cancer Drugs, 1997, 8, 702-707.	1.4	17
88	TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochemical and Biophysical Research Communications, 2007, 362, 419-424.	2.1	17
89	The Utility of Poly(.GAMMAglutamic acid) Nanoparticles as Antigen Delivery Carriers in Dendritic Cell-Based Cancer Immunotherapy. Biological and Pharmaceutical Bulletin, 2010, 33, 2003-2007.	1.4	17
90	Analysis of Transcutaneous Antigenic Protein Delivery by a Hydrogel Patch Formulation. Journal of Pharmaceutical Sciences, 2013, 102, 1936-1947.	3.3	17

#	Article	IF	CITATIONS
91	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Molecular Therapy - Oncolytics, 2016, 3, 16024.	4.4	17
92	Analysis of Skin Permeability and Toxicological Properties of Amorphous Silica Particles. Biological and Pharmaceutical Bulletin, 2016, 39, 1201-1205.	1.4	16
93	Antimetastatic effects of synthetic peptides containing the core sequence of the type III connecting segment domain (IIICS) of fibronectin. Anti-Cancer Drugs, 1994, 5, 424-428.	1.4	15
94	A Quantitativein vivoMethod of Analyzing Human Tumor-induced Angiogenesis in Mice Using Agarose Microencapsulation and Hemoglobin Enzyme-linked Immunosorbent Assay. Japanese Journal of Cancer Research, 1995, 86, 1182-1188.	1.7	15
95	Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sciences, 2008, 83, 747-755.	4.3	15
96	Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy. Biochemical and Biophysical Research Communications, 2016, 473, 73-79.	2.1	15
97	Excellent Absorption Enhancing Characteristics of NO Donors for Improving the Intestinal Absorption of Poorly Absorbable Compound Compared with Conventional Absorption Enhancers. Drug Metabolism and Pharmacokinetics, 2006, 21, 222-229.	2.2	14
98	Evaluation of Angiogenic Inhibitors with anin vivoQuantitative Angiogenesis Method Using Agarose Microencapsulation and Mouse Hemoglobin Enzyme-linked Immunosorbent Assay. Japanese Journal of Cancer Research, 1996, 87, 952-957.	1.7	13
99	Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor. Biochemical and Biophysical Research Communications, 2008, 372, 821-825.	2.1	13
100	Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials, 2010, 31, 3357-3363.	11.4	13
101	Therapeutic Effect of Cytomedicine on Mesangio-Proliferative Glomerulonephritis in Human Interleukin-6 Transgenic Mice Biological and Pharmaceutical Bulletin, 1997, 20, 255-258.	1.4	12
102	Creation of lysine-deficient mutant lymphotoxin- $\hat{l}_{\pm}$ with receptor selectivity by using a phage display system. Biomaterials, 2010, 31, 1935-1943.	11.4	12
103	Immunogenicity of Milk Protein-Containing Hydrophilic Gel Patch for Epicutaneous Immunotherapy for Milk Allergy. Pharmaceutical Research, 2020, 37, 35.	3.5	12
104	A novel cytomedical vehicle capable of protecting cells against complement. Biochemical and Biophysical Research Communications, 2003, 305, 353-358.	2.1	11
105	Adenovirus Vector Covalently Conjugated to Polyethylene Glycol with a Cancer-Specific Promoter Suppresses the Tumor Growth through Systemic Administration. Biological and Pharmaceutical Bulletin, 2010, 33, 1073-1076.	1.4	11
106	Compositional Optimization and Safety Assessment of a Hydrogel Patch as a Transcutaneous Immunization Device. Biological and Pharmaceutical Bulletin, 2011, 34, 1835-1840.	1.4	11
107	Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant. Pharmaceutics, 2020, 12, 267.	4.5	11
108	Selective Enhancement by Tumor Necrosis Factor-α of Vascular Permeability of New Blood Vessels Induced with Agarose Hydrogel-entrapped Meth-A Fibrosarcoma Cells. Japanese Journal of Cancer Research, 1996, 87, 831-836.	1.7	10

#	Article	IF	CITATIONS
109	Combination of two fiber-mutant adenovirus vectors, one encoding the chemokine FKN and another encoding cytokine interleukin 12, elicits notably enhanced anti-tumor responses. Cancer Immunology, Immunotherapy, 2008, 57, 1657-1664.	4.2	10
110	Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor. Biochemical and Biophysical Research Communications, 2010, 393, 888-893.	2.1	10
111	Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals. International Journal of Molecular Sciences, 2021, 22, 2476.	4.1	10
112	Medical application of microencapsulating hybridoma cells in agarose microbeads `cytomedicine': therapeutic effect on IgG1 plasmacytosis and mesangio-proliferative glomerulonephritis in the interleukin 6 transgenic mouse. Journal of Controlled Release, 1997, 44, 195-200.	9.9	9
113	LIGHT protein suppresses tumor growth by augmentation of immune response. Immunology Letters, 2009, 127, 33-38.	2.5	9
114	Characteristics of immune induction by transcutaneous vaccination using dissolving microneedle patches in mice. International Journal of Pharmaceutics, 2021, 601, 120563.	5.2	9
115	Prolongation of the Effective Duration of Cytomedical Therapy by Re-injecting SK2 Hybridoma Cells Microencapsulated within Alginate-Poly(L)lysine-Alginate Membranes into Human Interleukin-6 Transgenic Mice Biological and Pharmaceutical Bulletin, 1999, 22, 295-297.	1.4	8
116	Development of a Novel Cytomedical Treatment that can Protect Entrapped Cells from Host Humoral Immunity. Cell Transplantation, 2002, 11, 787-797.	2.5	8
117	Factors involved in the maturation of murine dendritic cells transduced with adenoviral vector variants. Virology, 2008, 374, 411-420.	2.4	8
118	Enhanced Permeability of Phenylalanyl-glycine (Phe-Gly) Across the Intestinal Membranes by Chemical Modification with Various Fatty Acids. Drug Metabolism and Pharmacokinetics, 2003, 18, 23-32.	2.2	7
119	Cell Delivery System: A Novel Strategy to Improve the Efficacy of Cancer Immunotherapy by Manipulation of Immune Cell Trafficking and Biodistribution. Biological and Pharmaceutical Bulletin, 2005, 28, 1543-1550.	1.4	7
120	The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity. International Journal of Molecular Sciences, 2022, 23, 4056.	4.1	7
121	Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2. Biochemical and Biophysical Research Communications, 2010, 394, 54-58.	2.1	6
122	Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting) Tj ETQq0 0 0	rgBT/Ove	rlock 10 Tf 50
123	Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8+ T cell responses. Journal of Pharmacological Sciences, 2020, 143, 182-187.	2.5	6
124	Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. Journal of Pharmacy and Pharmacology, 2008, 60, 1633-1641.	2.4	6
125	Combination effects of complement regulatory proteins and anti-complement polymer. Biochimica Et Biophysica Acta - General Subjects, 2003, 1624, 54-59.	2.4	4
126	Fusogenic liposomes and their suitability for gene delivery. Future Lipidology, 2006, 1, 735-742.	0.5	4

#	Article	IF	CITATIONS
127	Ligand-independent assembly of purified soluble magic roundabout (Robo4), a tumor-specific endothelial marker. Protein Expression and Purification, 2008, 61, 78-82.	1.3	4
128	Modifying the antigen-immunization schedule improves the variety of monoclonal antibodies obtained from immune-phage antibody libraries against HIV-1 Nef and Vif. Journal of Bioscience and Bioengineering, 2011, 111, 597-599.	2.2	4
129	Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy. Cytokine, 2013, 61, 578-584.	3.2	4
130	Enhanced absorption of insulin and (Asu1,7)eelâ€calcitonin using novel azopolymerâ€coated pellets for colonâ€specific drug delivery. Journal of Pharmaceutical Sciences, 2001, 90, 89-97.	3.3	4
131	Targeting GGT1 Eliminates the Tumor-Promoting Effect and Enhanced Immunosuppressive Function of Myeloid-Derived Suppressor Cells Caused by G-CSF. Frontiers in Pharmacology, 2022, 13, 873792.	3.5	4
132	Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation. Cytokine, 2011, 56, 489-493.	3.2	3
133	Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models. International Immunopharmacology, 2010, 10, 26-33.	3.8	2
134	Structure–activity relationship of T-cell receptors based on alanine scanning. Biochemical and Biophysical Research Communications, 2011, 415, 558-562.	2.1	2
135	Development and functional analysis of an anticancer Tâ€cell medicine with immune checkpoint inhibitory ability. IUBMB Life, 2020, 72, 1649-1658.	3.4	2
136	Analysis of immune response induction mechanisms implicating the dose-sparing effect of transcutaneous immunization using a self-dissolving microneedle patch. Vaccine, 2022, 40, 862-872.	3.8	1
137	Transcutaneous Administration of Imiquimod Promotes T and B Cell Differentiation into Effector Cells or Plasma Cells. Pharmaceutics, 2022, 14, 385.	4.5	1
138	Binding and Efficacy of Anti-Robo4 CAR-T Cells against Solid Tumors. Biomedicines, 2022, 10, 1273.	3.2	1
139	Development of a Patch Vaccine Formulation Utilizing the Microneedle Technology. Journal of the Japan Society for Precision Engineering, 2016, 82, 1023-1026.	0.1	0
140	Related Topic: Vaccines. , 2017, , 281-288.		0
141	Development of transcutaneous vaccine formulations based on DDS technology. Drug Delivery System, 2010, 25, 8-14.	0.0	0
142	Potential of epicutaneous immunotherapy using a novel device. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2015, 29, 49-53.	0.2	0
143	Adjuvant Activity of CpG-Oligonucleotide Administered Transcutaneously in Combination with Vaccination Using a Self-Dissolving Microneedle Patch in Mice. Vaccines, 2021, 9, 1480.	4.4	0